Interim analysis
lung cancer, toxicities, Toxicities, toxicity
LUNG CANCER
An Independent Data Monitoring Committee (IDMC) will be established for the trial. This IDMC will meet after the inclusion of 10 patients with 5 weeks of follow-up in each cohort to evaluate toxicities, except for the lung cancer cohort, which will be evaluated during phase I. Toxicities will be described by grade and type of toxicity for each patient, focusing on the same DLT as described for phase I. The purpose of this interim analysis is to validate with the IDMC the safety of the combination of immunotherapy and radiation. Inclusion will be stopped while waiting for the IDMC meeting and decision. No interim analysis is planned for efficacy.